These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1937192)

  • 21. Hypertension in the elderly: 24 h ambulatory blood pressure results from a placebo-controlled trial.
    Neutel JM; Smith DH; Lefkowitz MP; Cargo P; Alemayehu D; Weber MA
    J Hum Hypertens; 1995 Sep; 9(9):723-7. PubMed ID: 8551485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension.
    Levine JH; Ferdinand KC; Cargo P; Laine H; Lefkowitz M
    Am J Hypertens; 1995 May; 8(5 Pt 1):494-9. PubMed ID: 7662226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of sustained-release-L-arginine formulation on blood pressure and vascular compliance in 29 healthy individuals.
    Miller AL
    Altern Med Rev; 2006 Mar; 11(1):23-9. PubMed ID: 16597191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the Vital Signs Quality of Life Questionnaire in three studies on hypertension.
    Kong BW; Bean JA; Stephens D
    J Hum Hypertens; 1995 Apr; 9(4):255-62. PubMed ID: 7595908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of amlodipine and the nifedipine retard preparation in the treatment of arterial hypertension].
    Pivac N; Dobovisek J; Bagatin J; Gros Furek V; Rumboldt Z; Janezić A; Kveder R; Sjerobabski V; Simunić M; Sardelić S
    Lijec Vjesn; 1993; 115(11-12):356-9. PubMed ID: 8176999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Verapamil compared with nifedipine in the treatment of essential hypertension.
    Midtbø K; Hals O; van der Meer J
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S363-8. PubMed ID: 6184569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Open study on the effect and side effects of indoramin, used at the 2d and 3d therapeutic step in essential hypertension].
    Hitzenberger G; Korn A
    Wien Med Wochenschr; 1985 Sep; 135(17):425-30. PubMed ID: 4060742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension.
    Svetkey LP; Weinberger MH; Gavras H; Gavras I; Brown TS; Deterding J; Klotman PE
    J Clin Hypertens; 1987 Dec; 3(4):579-88. PubMed ID: 3330988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy and tolerability of isoptine LP in mild to moderate hypertension. A multicenter study with 50 patients].
    Boutarin J; Maarek-Charbit M; Aupetit JF; Galey-Arcangioli C; Ritz B
    Ann Cardiol Angeiol (Paris); 1992 Dec; 41(10):587-93. PubMed ID: 1300922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil.
    Davis PJ; Fagan TC; Topmiller MJ; Levine JH; Ferdinand KC
    J Clin Pharmacol; 1995 Jan; 35(1):52-8. PubMed ID: 7751413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of verapamil for hypertension by an isometric exercise test].
    Cantor A; Katz A; Gold B; Gilutz H
    Harefuah; 1991 Nov; 121(10):369-73. PubMed ID: 1752552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of mild to moderate hypertension with verapamil slow-release in outpatients. Collaborative Group of the Spanish League for the Fight Against Hypertension.
    Gómez Pajuelo C; Pérez Naranjo J; Ruiz Martínez I
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S50-2. PubMed ID: 2475687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. The Verapamil-SR Study Group.
    McMahon FG; Reder RF
    J Clin Pharmacol; 1989 Nov; 29(11):1003-7. PubMed ID: 2689469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained-release verapamil as a first-step drug in the treatment of mild to moderate hypertension.
    Karcier SM; Orbay B; Ozder AB; Gürses N; Aytekin S; Satar S; Oztürk M; Demiroğlu C
    J Int Med Res; 1989; 17(3):268-76. PubMed ID: 2767329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentration/effect relationship and enantioselective analysis of verapamil in hypertensive patients.
    Harder S; Thürmann P; Siewert M; Blume H; Rietbrock N; vander Kleijn J; Gierend M
    J Cardiovasc Pharmacol; 1992 May; 19(5):665-9. PubMed ID: 1381762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of sustained-release formulations of nicardipine and verapamil for mild to moderate systemic hypertension.
    Gradman AH; Frishman WH; Kaihlanen PM; Wong SC; Friday KJ
    Am J Cardiol; 1992 Dec; 70(20):1571-5. PubMed ID: 1466325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    Drugs; 1992; 44 Suppl 1():1-11. PubMed ID: 1283570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study.
    Speders S; Sosna J; Schumacher A; Pfennigsdorf G
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S47-9. PubMed ID: 2475686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute toxic effects of sustained-release verapamil in chronic renal failure.
    Pritza DR; Bierman MH; Hammeke MD
    Arch Intern Med; 1991 Oct; 151(10):2081-4. PubMed ID: 1843183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of 'once daily' verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recording.
    Caruana M; Heber M; Brigden G; Raftery EB
    Eur J Clin Pharmacol; 1987; 32(6):549-53. PubMed ID: 3653223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.